This inventor holds 5 USPTO granted patents and 1 published patent application, plus 1 CIPO patent and 4 EPO patents. Top assignees: Pharmeste S.r.l., Serentrix, LLC. Active years: 2010-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Ferrara, IT (2010 - 2012)
- Gavello di Bondeno, IT (2015 - 2019)
Company Filing History:
Years Active: 2010-2019
Title: The Innovative Contributions of Marcello Trevisani
Introduction
Marcello Trevisani is a notable inventor based in Ferrara, Italy. He has made significant contributions to the field of pharmaceuticals, particularly in the development of TRPV1 vanilloid receptor antagonists. With a total of 5 patents, Trevisani's work has the potential to impact the treatment of pain and various medical conditions.
Latest Patents
Trevisani's latest patents focus on compounds that serve as TRPV1 antagonists. These compounds, described in his patent as formula I, are useful as active ingredients in pharmaceutical compositions aimed at treating pain and other conditions that can be alleviated by inhibiting the vanilloid receptor TRPV1. His innovative approach in this area highlights the importance of TRPV1 antagonists in modern medicine.
Career Highlights
Throughout his career, Trevisani has worked with various companies, including Pharmeste S.r.l. and Serentrix, LLC. His experience in these organizations has allowed him to refine his expertise and contribute to groundbreaking research in the pharmaceutical industry.
Collaborations
Trevisani has collaborated with several professionals in his field, including Maria Giovanna Pavani and Francesca Fruttarolo. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Marcello Trevisani's contributions to the field of pharmaceuticals, particularly through his patents on TRPV1 antagonists, demonstrate his commitment to advancing medical science. His work continues to pave the way for new treatments that can improve the quality of life for many individuals.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile